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1
ABSTRACT 31 
These authors contributed equally to this work. 30 
Aldosterone synthase is the key rate-limiting enzyme in adrenal aldosterone production, 32 
and induction of its gene (CYP11B2) results in the progression of hypertension. As 33 
hypertension is a frequent complication among diabetes patients, we set out to elucidate 34 
the link between diabetes mellitus and hypertension. We examined the effects of high 35 
glucose on CYP11B2 expression and aldosterone production using human adrenal 36 
H295R cells and a stable H295R cell line expressing a CYP11B2 5’-flanking 37 
region/luciferase cDNA chimeric construct. D-glucose, but not its enantiomer L-glucose, 38 
dose-dependently induced CYP11B2 transcription and mRNA expression. A high 39 
concentration (450 mg/dL) of D-glucose time-dependently induced CYP11B2 40 
transcription and mRNA expression. Moreover, high glucose stimulated secretion of 41 
aldosterone into the media. Transient transfection studies using deletion 42 
mutants/NBRE-1 point mutant of CYP11B2 5’-flanking region revealed that the 43 
NBRE-1 element, known to be activated by transcription factors NGFIB and NURR1, 44 
was responsible for the high glucose-mediated effect. High glucose also induced the 45 
mRNA expression of these transcription factors, especially that of NURR1, but NURR1 46 
knockdown using its siRNA did not affect high glucose-induced CYP11B2 mRNA 47 
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expression. Taken together, it is speculated that high glucose may induce CYP11B2 48 
transcription via the NBRE-1 element in its 5’-flanking region, resulting in the increase 49 
of aldosterone production although high glucose-induced NURR1 is not directly 50 
involved in the effect. Additionally, glucose metabolism and calcium channels were 51 
found to be involved in the high glucose effect. Our observations suggest one possible 52 
explanation for the high incidence of hypertension in diabetic patients. 53 
 54 
Keywords: Aldosterone synthase, NURR1, Hypertension, Diabetes mellitus 55 
 56 
Abbreviations: NURR1, Nur-related factor 1; NGFIB, nerve growth factor-induced 57 
clone B; NBRE, NGFIB response element; SF-1, steroidogenic factor-1; CREB, 58 
cAMP-response element binding protein; CREM, cAMP- response element modulator; 59 
COUP-TF, chicken ovalbumin upstream promoter transcription factor; ATF, activating 60 
transforming factor; ARB, angiotensin II receptor blocker; CCB, calcium channel 61 
blocker. 62 
 63 
Running heading: Effects of high glucose on CYP11B2 expression  64 
 65 
 66 
1. Introduction 67 
 68 
The number of patients with diabetes mellitus is increasing every year, and 382 69 
million people in the world were estimated to be affected in 2013 [1]. Among diabetic 70 
patients, hypertension is one of the most frequently observed complications. In Japan, 71 
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the incidence of hypertension in diabetic patients is approximately 60%, which is twice 72 
that in non-diabetic people [2]. The etiology of hypertension in diabetic patients is 73 
partially explained by the effect of hyperinsulinemia on renal proximal tubules due to 74 
insulin resistance [3]. Additionally, endothelial dysfunction and atherosclerosis induced 75 
by diabetes mellitus may also contribute to the progression of hypertension [4]. 76 
However, the direct involvement of high glucose on the etiology of hypertension in 77 
diabetic patients still remains uncertain.  78 
The renin-angiotensin-aldosterone system (RAAS) is known as the main humoral 79 
pathway involved in the etiology of hypertension, and aldosterone, the final product of 80 
the pathway, plays an important role in the progression of hypertension and vascular 81 
damages in combination with sodium [5]. Aldosterone is synthesized in the zona 82 
glomerulosa of the adrenal cortex from cholesterol catalyzed via side chain cleavage 83 
enzyme (CYP11A1), 3β-hydroxysteroid dehydrogenase (3β-HSD), steroid 84 
21-hydroxylase (CYP21), and aldosterone synthase (CYP11B2), which is the key 85 
rate-limiting enzyme in aldosterone production [6]. Aldosterone synthase gene 86 
(CYP11B2) expression is mainly regulated by angiotensin II (AII) and potassium via 87 
transcription factors including NURR1 [7]. Recently, genetic analyses of KCNJ5, 88 
ATP1A1, ATP2B3, and CACNA1D have revealed that chronic overexpression of 89 
CYP11B2 induces not only aldosterone hypersecretion but also the formation of primary 90 
aldosteronism [8], resulting in the progression of severe hypertension. Moreover, 91 
aberrant WNT signaling caused by mutations in CTNNB1 has also been recognized to 92 
be involved in the formation of primary aldosteronism [9]. In order to investigate the 93 
direct link between hypertension and diabetes mellitus, we here examined the effects of 94 
high glucose on CYP11B2 expression and aldosterone secretion using human adrenal 95 
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H295R cells.  96 
 97 
 98 
 99 
 100 
 101 
 102 
2. Materials and methods 103 
 104 
2.1. Reagents 105 
 106 
D-glucose was purchased from Wako (Osaka, Japan), and L-glucose, used for the 107 
adjustment of osmolality, was purchased from Sigma (St. Louis, MO). 108 
2-deoxy-D-glucose, D-sorbitol, D-fructose, and 3-O-methyl-D-glucose were purchased 109 
from Sigma. Olmesartan (olmesartan medoxomil) was purchased from Toronto 110 
Research Chemicals (North York, Canada). Losartan (losartan potassium) was 111 
purchased from LKT Laboratories (St. Paul, MN). Valsartan was purchased from 112 
Cayman Chemical (Ann Arbor, MI). Candesartan (trityl candesartan ciletexitil) was 113 
purchased from Sequoia Research Products (Pangbourne, UK). Nifedipine and 114 
efonidipine (efonidipine hydrochloride monoethanolate) were purchased from Sigma. 115 
Amlodipine was purchased from Cayman Chemical. Benidipine (benidipine 116 
hydrochloride) was kindly provided by Kyowa Hakko Kirin Pharma (Tokyo, Japan). 117 
Human AII was purchased from Sigma. 118 
 119 
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2.2. Plasmids 120 
 121 
Subcloned chimeric constructs containing the human CYP11B2 genomic DNA and 122 
luciferase cDNA (pGL3-Basic, Promega, Madison, WI) [7, 10] were used for the 123 
transient transfection studies: -1521/+2-luc (harboring the CYP11B2 5’-flanking region 124 
from -1521 to +2 relative to the transcription start site upstream of the luciferase cDNA 125 
in pGL3-Basic), -747/+2-luc; -135/+2-luc; -106/+2-luc; -65/+2-luc. The NBRE-1 126 
mutant construct of -1521/+2-luc (NBRE-1 mut) was also used [11]. In some 127 
experiments, a previously described stable H295R cell line expressing CYP11B2 128 
promoter (-1521/+2)/luciferase chimeric reporter construct (CYP11B2-H295R cells) was 129 
used [7]. β-galactosidase control plasmid in pCMV (pCMV-β-gal) was purchased from 130 
Clontech (Palo Alto, CA).   131 
 132 
2.3. Cell culture 133 
 134 
H295R cells or CYP11B2-H295R cells were grown with a 1:1 mixture of DMEM 135 
and Ham’s F12 medium supplemented with 10% fetal bovine serum (FBS), 136 
Insulin-Transferrin-Selenium-G Supplements (Invitrogen, Carlsbad, CA), 1.25 mg/mL 137 
BSA (Sigma), 5.35 μg/mL linoleic acid (Sigma), 100 U/mL penicillin, 100 µg/mL 138 
streptomycin. Cells were cultured in a humidified incubator at 37°C with 5% CO2. 139 
Since the D-glucose concentration in the media was approximately 100 mg/dL, we 140 
added either concentrated D-glucose or L-glucose solution to adjust the final 141 
concentration. For example, the 450 mg/dL D-glucose concentration was composed of 142 
100 mg/dL D-glucose from the media and 350 mg/dL D-glucose from the concentrated 143 
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D-glucose solution, and its osmolality-adjusted control was composed of 100 mg/dL 144 
D-glucose from the media and 350 mg/dL L-glucose from the concentrated L-glucose 145 
solution. In some experiments, 2-deoxy-D-glucose, 3-O-methyl-D-glucose, D-sorbitol, 146 
or D-fructose was used instead of L-glucose. Moreover, CYP11B2-H295R cells were 147 
incubated either with angiotensin II receptor blockers (ARBs) or calcium channel 148 
blockers (CCBs) in the presence of 450 mg/dL D-glucose. 149 
 150 
2.4. RNA Preparation and quantitative real-time PCR 151 
 152 
When H295R cells were grown to 60% confluence in 24-multiwell plates, they 153 
were exposed to several concentrations of D-glucose or D-glucose plus L-glucose for 154 
the indicated times, and their total RNA was extracted using Sepasol®-RNA I Super G 155 
(Nacalai Tesque, Kyoto, Japan) according to the manufacturer’s instructions. Total 156 
RNAs were subjected to reverse transcription (RT) reaction using PrimeScript Reverse 157 
Transcriptase (Takara Bio, Ohtsu, Japan) with random 6mer and oligo dT primers 158 
according to the manufacturer’s instructions. Thereafter, the obtained templates were 159 
used for quantitative real-time PCR (95 °C, 3 min for 1 cycle; 95 °C, 15 sec; 60 °C, 10 160 
sec; 72 °C, 20 sec for 40 cycles) either with iQ Supermix (Bio-Rad, Hercules, CA) (for 161 
CYP11B2, CYP11B1, HSD3B2, and CYP17) or THUNDERBIRD® SYBR®
 166 
 qPCR Mix 162 
(TOYOBO, Osaka, Japan) (for others) by DNA Engine thermal cycler attached to 163 
Chromo4 detector (Bio-Rad). The sequences of the primers and TaqMan probes are 164 
shown in Table 1.  165 
2.5. Transient transfection and luciferase assay 167 
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 168 
H295R cells were plated to 60% confluence in 24-multiwell plates. Thereafter, they 169 
were transiently transfected with 200 ng luciferase reporter plasmids and 100 ng 170 
pCMV-β-gal using Lipofectamine®
 179 
 2000 Transfection Reagent (Life Technologies, 171 
Carlsbad, CA) for 24 hours. The cells were then exposed to D-glucose or L-glucose for 172 
the indicated times and concentrations. They were thereafter washed with PBS, and the 173 
cell extracts were prepared using Glo Lysis Buffer (Promega). Luciferase activity was 174 
measured using Bright-Glo reagents (Promega), and β-galactosidase activity was 175 
simultaneously measured. Data were normalized by the β-galactosidase activities. When 176 
the stable CYP11B2-H295R cells [7] were used, only the luciferase activity was 177 
measured 178 
2.6. Small interfering RNA transfection 180 
 181 
Small interfering RNA (siRNA) for NURR1 (s9785) [12] was obtained from 182 
Thermo Fisher Scientific (Waltham, MA), and negative control siRNA (SI03650318) 183 
was obtained from Qiagen (Hilden, Germany). H295R cells were plated to 60% 184 
confluence in 12-multiwell plates. Thereafter, they were transiently transfected with 10 185 
pmol of each siRNA by electroporation using Nucleofector 4DTM
 188 
 (Lonza, Basel, 186 
Switzerland) as previously described [13]. 187 
2.7. Measurement of aldosterone/cortisol concentration 189 
 190 
H295R cells were plated to 60% confluence in 24-multiwell plates. Thereafter, they 191 
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were exposed to either 100 mg/dL D-glucose, 450 mg/dL D-glucose, 100 mg/dL 192 
D-glucose plus 100 nmol/L AII (for aldosterone), or 450 mg/dL D-glucose plus 100 193 
nmol/L AII (for aldosterone) for 72 hours. The aldosterone and cortisol concentrations 194 
of the media were thereafter measured by Aldosterone EIA Kit and Cortisol EIA Kit 195 
(Cayman Chemical), respectively after their extraction with dichloromethane according 196 
to the manufacturer's instructions. The obtained data were normalized by the protein 197 
concentrations measured by Protein Assay Kit (Bio-Rad). 198 
 199 
2.8. Statistical analyses 200 
 201 
All data are presented as mean ± SEM. For the statistical analyses, ANOVA 202 
followed by post hoc Tukey test was performed. P<0.05 was considered statistically 203 
significant. 204 
 205 
 206 
 207 
 208 
 209 
 210 
3. Results 211 
 212 
3.1. Effects of high glucose on CYP11B2 expression and aldosterone 213 
secretion 214 
 215 
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We first examined the effects of high glucose on CYP11B2 mRNA expression using 216 
H295R cells. As shown in Fig. 1A, D-glucose levels above 270 mg/dL significantly 217 
induced CYP11B2 mRNA expression. Time course experiments in the presence of 450 218 
mg/dL D-glucose demonstrated that high glucose induced CYP11B2 mRNA expression 219 
after 48 hours (Fig. 1B). We next examined the effect of high glucose on CYP11B2 220 
transcription using stable CYP11B2-H295R cells [7], and also observed similar 221 
stimulatory effects in both the dose response (Fig. 1C) and time course (Fig. 1D) 222 
experiments. We also examined the effect of high glucose (450 mg/dL D-glucose) on 223 
the mRNA expression of other enzymes/protein involved in adrenal steroidogenesis. As 224 
shown in Fig. 2, high glucose treatment significantly induced the mRNA expression of 225 
11β-hydroxylase gene (CYP11B1) (A) and steroidogenic acute regulatory protein gene 226 
(StAR) (E) after 48 hours incubation, while high glucose treatment significantly 227 
decreased that of CYP11A1 (D) after 24 hours incubation. High glucose treatment did 228 
not affect the mRNA expression of 3β-HSD gene (HSD3B2) (B) and CYP21 (C), while 229 
it tended to decrease, although not significantly, the expression of 230 
17α-hydroxylase/17,20 lyase gene (CYP17) (F). We then examined the effect of high 231 
glucose on aldosterone secretion from H295R cells. As shown in Fig. 3A, incubation of 232 
the cells in the presence of 450 mg/dL D-glucose for 72 hours significantly induced 233 
aldosterone secretion into the media, which was comparable to the AII-induced 234 
aldosterone secretion. Incubation with 450 mg/dL D-glucose plus AII did not further 235 
increase the aldosterone secretion (Fig. 3A). It can be concluded that high glucose 236 
induces CYP11B2 transcription and mRNA expression resulting in the increase of 237 
aldosterone secretion. In contrast, although high glucose induced the mRNA expression 238 
of CYP11B1 (Fig. 2A), it did not induce cortisol secretion into the media (Fig. 3B) 239 
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probably due to the decreasing trend of CYP17 mRNA expression (Fig. 2F).  240 
 241 
3.2. Identification of the element(s) responsible for the high 242 
glucose-induced CYP11B2 transactivation 243 
 244 
In order to identify the element(s) responsible for the high glucose-induced 245 
CYP11B2 transactivation, we examined the effects of high glucose on the promoter 246 
activity of CYP11B2 5’-flanking region deletion mutants by comparing the effects 247 
between D-glucose (450 mg/dL) and L-glucose (100 mg/dL D-glucose and 350 mg/dL 248 
L-glucose) using H295R cells. As shown in Fig. 4A, although high glucose-induced 249 
CYP11B2 transactivation was significantly observed in -1521/+2-luc, it was not 250 
observed in -747/+2-luc, -135/+2-luc, -106/+2-luc, or -65/+2-luc. These data indicate 251 
that the region between -1521 and -747 may be responsible for the high glucose effect. 252 
Since NBRE-1 element [11], which is known to be transactivated by NURR1 and 253 
NGFIB [11, 14], is located within the region (-766/-759), we next examined the effect 254 
of high glucose on the element. As shown in Fig. 4B, point mutation of NBRE-1 255 
element (NBRE-1 mut) completely abolished the high glucose effect. These data 256 
indicate that the element responsible for the high glucose-induced CYP11B2 257 
transactivation may possibly be the NBRE-1 element.  258 
 259 
3.3. Effects of high glucose on the expression of transcription factors 260 
involved in CYP11B2 transcription 261 
 262 
We next examined the effects of high glucose on the mRNA expression of 263 
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transcription factors that are known to regulate CYP11B2 promoter [14] using H295R 264 
cells. As shown in Fig. 5A, D-glucose (450 mg/dL), but not control (100 mg/dL 265 
D-glucose) or L-glucose (100 mg/dL D-glucose and 350 mg/dL L-glucose), 266 
significantly induced the expression of NURR1 mRNA. D-glucose also induced the 267 
mRNA expression of NGFIB (Fig. 5B), but not that of SF-1 (Fig. 5C), CREB (Fig. 5D), 268 
CREM (Fig. 5E), COUP-TF (Fig. 5F), ATF-1 (Fig. 5G), or ATF-2 (Fig. 5H). Since 269 
NURR1 is known to bind to NBRE-1 and activate it [11], it is indicated that high 270 
glucose-induced NURR1 may transactivate CYP11B2 expression via the NBRE-1 271 
element. 272 
 273 
3.4. Effects of NURR1 siRNA on the high glucose-induced CYP11B2 mRNA 274 
expression 275 
 276 
In order to examine the involvement of NURR1 in the high glucose-induced 277 
CYP11B2 mRNA expression, we next transfected either the control or NURR1 siRNA 278 
into H295R cells, and thereafter treated the cells with 450 mg/dL D-glucose for 48 279 
hours. As shown in Fig. 6A, NURR1 mRNA expression was significantly decreased by 280 
the transfection of NURR1 siRNA as compared to that of control siRNA in the presence 281 
of either 100 mg/dL D-glucose or 450 mg/dL D-glucose, suggesting the efficient 282 
knockdown of endogenous NURR1 mRNA. However, NURR1 knockdown by its 283 
siRNA transfection did not affect the high glucose-induced CYP11B2 mRNA expression 284 
in comparison to control siRNA transfection (Fig. 6B). These data indicate that other 285 
NR4A family members or other transcription factors may be involved in the high 286 
glucose-induced CYP11B2 mRNA expression via the NBRE-1 element. 287 
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 288 
3.5. Effects of 2-deoxy-D-glucose, 3-O-methyl-D-glucose, D-sorbitol, and 289 
D-fructose on CYP11B2 mRNA expression 290 
 291 
We next examined the involvement of glucose metabolism on the high 292 
glucose-induced CYP11B2 expression. When we treated H295R cells with either 293 
2-deoxy-D-glucose, which could be phosphorylated but could not be metabolized 294 
further [15, 16], or 3-O-methyl-D-glucose, which could not be phosphorylated [16], the 295 
induction of CYP11B2 mRNA expression was not observed (Fig. 7). These data suggest 296 
that D-glucose metabolization may be more necessary for the induction than glucose 297 
6-phosphate. Moreover, incubation with D-sorbitol or D-fructose, both of which are 298 
D-glucose metabolites via the polyol pathway [17], did not affect CYP11B2 mRNA 299 
expression (Fig. 7) indicating that the pathway may not be involved in the induction. 300 
 301 
3.6. Effects of ARBs and CCBs on the high glucose-induced CYP11B2 302 
transcription 303 
 304 
We next examined the effects of ARBs and CCBs on the high glucose-induced 305 
CYP11B2 transcription. As shown in Fig. 8A, each ARB at 1 µmol/L did not affect the 306 
high glucose effect. In contrast, each CBB dose-dependently inhibited the high 307 
glucose-induced CYP11B2 transactivation (Fig. 8B). It is therefore suggested that 308 
calcium channels, but not AII type 1 receptor, are involved in the high glucose effect. 309 
 310 
 311 
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 312 
 313 
 314 
 315 
 316 
 317 
 318 
4. Discussion 319 
 320 
In the present study, we first demonstrated the stimulatory effect of high glucose on 321 
CYP11B2 transcription and mRNA expression as well as aldosterone secretion in human 322 
adrenal cells (Fig. 1, Fig. 3A). The high glucose-induced CYP11B2 mRNA expression 323 
was not observed when we used glucose analogs, 2-deoxy-D-glucose and 324 
3-O-methyl-D-glucose [15, 16] (Fig. 7), suggesting that it is necessary for D-glucose to 325 
be metabolized within the cells for the stimulatory effect. Since we also observed the 326 
high glucose-induced StAR mRNA expression (Fig. 2E), increased StAR and CYP11B2 327 
may coordinately induce aldosterone production. Aldosterone not only induces 328 
hypertension and vascular damage in combination with sodium [5], but is also known to 329 
inhibit glucose-induced insulin secretion in pancreatic ß-cells [18] as well as insulin 330 
signaling in peripheral tissues [19, 20]. Therefore, the high glucose-induced aldosterone 331 
may induce “a vicious cycle” in terms of the exacerbation of glucose 332 
intolerance/diabetes mellitus. Although the plasma aldosterone concentration in diabetic 333 
patients has long been controversial, it has recently been confirmed to be significantly 334 
higher than that of normal subjects by fixing sodium/potassium intake and the time for 335 
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drawing blood samples [21]. Therefore, based on our present observation, high 336 
glucose-induced aldosterone production may possibly contribute to the increased 337 
plasma aldosterone level in diabetic patients. 338 
Transient transfection experiments using CYP11B2 5’-flanking region deletion 339 
mutants and NBRE-1 point mutant revealed that the NBRE-1 element, which is known 340 
to be activated by NURR1/NGFIB binding [11, 14], was responsible for the high 341 
glucose-induced CYP11B2 transactivation (Fig. 4). Additionally, high glucose was 342 
demonstrated to induce the mRNA expression of NURR1 significantly compared with 343 
that of NGFIB (Fig. 5). However, since NURR1 knockdown did not affect the high 344 
glucose-induced CYP11B2 mRNA expression (Fig. 6), other NR4A family members or 345 
other transcription factors may bind to and activate NBRE-1 element to induce 346 
CYP11B2 transactivation. In human adrenocortical neoplasms, CYP11B2 mRNA 347 
expression significantly and positively correlated with NURR1 mRNA expression, but 348 
not with NGFIB mRNA expression [22]. Since H295R cells are also derived from 349 
human adrenocortical carcinoma, it is plausible that NURR1 also plays an indispensable 350 
role in CYP11B2 transactivation in the cells. Interestingly, high glucose was 351 
demonstrated to suppress SF-1 mRNA expression, although not significantly (Fig. 5C). 352 
Since SF-1 is known to suppress CYP11B2 transcription [23, 24], the high 353 
glucose-mediated SF-1 decrease may also contribute to the induction of CYP11B2 354 
transactivation. The mechanisms by which high glucose induce NURR1 mRNA 355 
expression remain uncertain. AII and potassium are two major factors that regulate 356 
CYP11B2 transcription [14, 25]. AII is known to bind to AII type 1 receptor and activate 357 
phospholipase C to increase inositol 1,4,5-trisphosphate (IP3), and IP3 induces the 358 
release of intracellular calcium from the endoplasmic reticulum, while potassium causes 359 
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depolarization of the membrane allowing extracellular cytoplasmic calcium influx 360 
through the T- and L-type calcium channels [14, 25]. In both cases, increased calcium 361 
leads to the activation of calcium/calmodulin-dependent kinase, resulting in the 362 
induction of NURR1 mRNA expression [14, 25]. When we treated the stable 363 
CYP11B2-H295R cells with several ARBs, the high glucose-induced CYP11B2 364 
transactivation was not affected (Fig. 8A). In contrast, when we treated the cells with 365 
several CCBs, they, especially benidipine that blocks both T- and L-type calcium 366 
channels [26], dose-dependently inhibited the high glucose-induced CYP11B2 367 
transactivation (Fig. 8B). These data indicate that high glucose may affect at least 368 
pathway(s) mediated via T- and/or L-type calcium channels, but not pathway(s) 369 
mediated via AII type 1 receptor. Interestingly, we have recently observed the high 370 
glucose-induced mRNA expression of T-type calcium channel subunits (CaV3.1, 371 
CaV3.2, and CaV3.3) [27], which may also be involved in the high glucose effect. 372 
Further studies are needed to clarify the precise molecular mechanisms of the high 373 
glucose-induced CYP11B2 transactivation. 374 
In summary, we here demonstrated high glucose-induced CYP11B2 transcription 375 
and mRNA expression as well as aldosterone secretion via NURR1 induction. Since our 376 
observation provides a novel insight in the etiology of hypertension in diabetic patients, 377 
it may also lead to novel therapeutics, such as an inhibitor of CYP11B2 transcription, for 378 
diabetic patients complicated with hypertension. 379 
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Figure legends 499 
Fig. 1. Effects of high glucose on CYP11B2 transcription and mRNA expression. (A) 500 
Dose-response effects of high glucose on CYP11B2 mRNA expression. H295R cells 501 
were incubated either with 100 mg/dL D-glucose, 100 mg/dL D-glucose plus 350 mg/dL 502 
L-glucose, 180 mg/dL D-glucose plus 270 mg/dL L-glucose, 270 mg/dL D-glucose plus 503 
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180 mg/dL L-glucose, 350 mg/dL D-glucose plus 100 mg/dL L-glucose, or 450 mg/dL 504 
D-glucose for 48 hours. Data represent mean ± SEM (n = 4), percent of 100 mg/dL 505 
D-glucose (control), normalized by β-actin mRNA levels. (B) Time-course effects of 506 
high glucose on CYP11B2 mRNA expression. H295R cells were incubated with 450 507 
mg/dL D-glucose for the indicated times. Data represent mean ± SEM (n = 4), percent 508 
of 0 hour (control), normalized by β-actin mRNA levels. (C) Dose-response effects of 509 
high glucose on CYP11B2 transcription. CYP11B2-H295R cells were incubated with 510 
several concentrations of D-glucose as in (A) for 48 hours. Data represent mean ± SEM 511 
(n = 4), percent of 100 mg/dL D-glucose (control). (D) Time-course effects of high 512 
glucose on CYP11B2 transcription. CYP11B2-H295R cells were incubated with 450 513 
mg/dL D-glucose for the indicated times. Data represent mean ± SEM (n = 4), percent 514 
of 0 hour (control). (A-D) * P < 0.01, vs. control. ** P < 0.05, vs. control.  515 
 516 
Fig. 2. Effects of high glucose on mRNA expression of enzymes/protein involved in 517 
adrenal steroidogenesis. Effects of high glucose on CYP11B1 mRNA expression (A), 518 
HSD3B2 mRNA expression (B), CYP21 mRNA expression (C), CYP11A1 mRNA 519 
expression (D), StAR mRNA expression (E), and CYP17 mRNA expression (F). H295R 520 
cells were incubated with 450 mg/dL D-glucose for the indicated times. Data represent 521 
mean ± SEM (n = 4), percent of 0 hour (control), normalized by β-actin mRNA levels. 522 
(A, D, E) * P < 0.01, vs. control. ** P < 0.05, vs. control.  523 
 524 
Fig. 3. Effects of high glucose on aldosterone and cortisol secretion. (A) Effects of high 525 
glucose and/or AII on aldosterone secretion. H295R cells were incubated with either 526 
100 mg/dL D-glucose, 450 mg/dL D-glucose, 100 mg/dL D-glucose plus 100 nmol/L 527 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
AII, or 450 mg/dL D-glucose plus 100 nmol/L AII for 72 hours. Data represent mean ± 528 
SEM (n = 4), percent of 100 mg/dL D-glucose (control), normalized by the protein 529 
concentrations. (B) Effects of high glucose on cortisol secretion. H295R cells were 530 
incubated with either 100 mg/dL D-glucose or 450 mg/dL D-glucose for 72 hours. Data 531 
represent mean ± SEM (n = 4), percent of 100 mg/dL D-glucose (control), normalized 532 
by the protein concentrations. Ang II; AII. (A) ** P < 0.05, vs. control. 533 
 534 
Fig. 4. Effects of 5’-flanking region mutants on the high glucose-induced CYP11B2 535 
transactivation. (A) Effects of CYP11B2 5’-flanking region deletion mutants. Either 536 
-1521/+2-luc, -747/+2-luc, -135/+2-luc, -106/+2-luc, -65/+2-luc, or pGL3-Basic 537 
(control plasmid) was transiently transfected with pCMV-β-gal into H295R cells, and 538 
the cells were incubated either with 450 mg/dL D-glucose (D-glucose, D-glu) or 100 539 
mg/dL D-glucose plus 350 mg/dL L-glucose (L-glucose, L-glu) for 48 hours. Data 540 
represent mean ± SEM (n = 4), percent of control (L-glucose), normalized by 541 
β-galactosidase activities. (B) Effects of NBRE-1 point mutant. Either -1521/+2-luc, 542 
NBRE-1 mut, or pGL3-Basic (control plasmid) was transiently transfected with 543 
pCMV-β-gal into H295R cells, and the cells were incubated either with 450 mg/dL 544 
D-glucose (D-glucose, D-glu) or 100 mg/dL D-glucose plus 350 mg/dL L-glucose 545 
(L-glucose, L-glu) for 48 hours. Data represent mean ± SEM (n = 4), percent of control 546 
(L-glucose), normalized by β-galactosidase activities. (A, B) * P < 0.01, vs. control. 547 
 548 
Fig. 5. Effects of high glucose on mRNA expression of transcription factors. Effects of 549 
high glucose on NURR1 mRNA expression (A), NGFIB mRNA expression (B), SF-1 550 
mRNA expression (C), CREB mRNA expression (D), CREM mRNA expression (E), 551 
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COUP-TF mRNA expression (F), ATF-1 mRNA expression (G), and ATF-2 mRNA 552 
expression (H). H295R cells were incubated either with 100 mg/dL D-glucose (control), 553 
100 mg/dL D-glucose plus 350 mg/dL L-glucose (L-glu), or 450 mg/dL D-glucose 554 
(D-glu) for 48 hours. Data represent mean ± SEM (n = 4), percent of 100 mg/dL 555 
D-glucose (control), normalized by the β-actin mRNA levels. (A) * P < 0.01, vs. control. 556 
(B) ** P < 0.05, vs. control. 557 
 558 
Fig. 6. Effects of NURR1 siRNA. Effects of NURR1 siRNA on NURR1 mRNA 559 
expression (A) and CYP11B2 mRNA expression (B). H295R cells transfected either 560 
with control siRNA (ctrl) or NURR1 siRNA (si NURR1) were incubated with either 100 561 
mg/dL D-glucose or 450 mg/dL D-glucose for 48 hours. In some experiments, 562 
untransfected H295R cells were incubated with 100 mg/dL D-glucose for 48 hours 563 
(base). Data represent mean ± SEM (n = 11), percent of 100 mg/dL D-glucose (base), 564 
normalized by GAPDH mRNA levels. (A, B) * P < 0.01. ** P < 0.05. 565 
 566 
Fig. 7. Effects of 2-deoxy-D-glucose, 3-O-methyl-D-glucose, D-sorbitol, and 567 
D-fructose on CYP11B2 mRNA expression. H295R cells were incubated either with 100 568 
mg/dL D-glucose plus 350 mg/dL L-glucose, 450 mg/dL D-glucose, 100 mg/dL 569 
D-glucose plus 350 mg/dL 2-deoxy-D-glucose, 100 mg/dL D-glucose plus 350 mg/dL 570 
3-O-methyl-D-glucose, 100 mg/dL D-glucose plus 350 mg/dL D-sorbitol, or 100 mg/dL 571 
D-glucose plus 350 mg/dL D-fructose for 72 hours. Data represent mean ± SEM (n = 4), 572 
percent of 100 mg/dL D-glucose plus 350 mg/dL L-glucose, normalized by the β-actin 573 
mRNA levels. * P < 0.01, vs. 100 mg/dL D-glucose plus 350 mg/dL L-glucose. ** P < 574 
0.01, vs. 450 mg/dL D-glucose. 575 
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 576 
Fig. 8. Effects of ARBs (A) and CCBs (B) on the high glucose-induced CYP11B2 577 
transactivation. In (A), CYP11B2-H295R cells were incubated either with 100 mg/dL 578 
D-glucose (control), 450 mg/dL D-glucose (D-glu), 450 mg/dL D-glucose plus 1 579 
µmol/L losartan (D-glu + Los), 450 mg/dL D-glucose plus 1 µmol/L valsartan (D-glu + 580 
Val), 450 mg/dL D-glucose plus 1 µmol/L olmesartan (D-glu + Olm), or 450 mg/dL 581 
D-glucose plus 1 µmol/L candesartan (D-glu + Can) for 48 hours. Data represent mean 582 
± SEM (n = 3), percent of control. * P < 0.01, vs. control. In (B), CYP11B2-H295R cells 583 
were incubated either with 100 mg/dL D-glucose, 450 mg/dL D-glucose, 450 mg/dL 584 
D-glucose plus 0.01 µmol/L amlodipine, 450 mg/dL D-glucose plus 0.1 µmol/L 585 
amlodipine, 450 mg/dL D-glucose plus 1 µmol/L amlodipine, 450 mg/dL D-glucose 586 
plus 0.01 µmol/L benidipine, 450 mg/dL D-glucose plus 0.1 µmol/L benidipine, 450 587 
mg/dL D-glucose plus 1 µmol/L benidipine, 450 mg/dL D-glucose plus 0.01 µmol/L 588 
efonidipine, 450 mg/dL D-glucose plus 0.1 µmol/L efonidipine, 450 mg/dL D-glucose 589 
plus 1 µmol/L efonidipine, 450 mg/dL D-glucose plus 0.01 µmol/L nifedipine, 450 590 
mg/dL D-glucose plus 0.1 µmol/L nifedipine or 450 mg/dL D-glucose plus 1 µmol/L 591 
nifedipine for 96 hours. Data represent mean ± SEM (n = 4), percent of 100 mg/dL 592 
D-glucose. * P < 0.01, vs. 100 mg/dL D-glucose. ** P < 0.05, vs. 450 mg/dL D-glucose. 593 
*** P < 0.01, vs. 450 mg/dL D-glucose.  594 
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